HUP9802320A2 - Macrolides, procedure of the preparation of macrolides, macrolides containing pharmaceutical products - Google Patents

Macrolides, procedure of the preparation of macrolides, macrolides containing pharmaceutical products

Info

Publication number
HUP9802320A2
HUP9802320A2 HU9802320A HUP9802320A HUP9802320A2 HU P9802320 A2 HUP9802320 A2 HU P9802320A2 HU 9802320 A HU9802320 A HU 9802320A HU P9802320 A HUP9802320 A HU P9802320A HU P9802320 A2 HUP9802320 A2 HU P9802320A2
Authority
HU
Hungary
Prior art keywords
macrolides
acid residue
procedure
preparation
pharmaceutical products
Prior art date
Application number
HU9802320A
Other languages
Hungarian (hu)
Inventor
Theodor Fehr
Lukas Oberer
Valerie Quesniaux Ryffel
Jean-Jacques Sanglier
Walter Schuler
Richard Sedrani
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9513596.8A external-priority patent/GB9513596D0/en
Priority claimed from GBGB9515495.1A external-priority patent/GB9515495D0/en
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP9802320A2 publication Critical patent/HUP9802320A2/en
Publication of HUP9802320A3 publication Critical patent/HUP9802320A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces

Abstract

A találmány makrőlidőkra, előállításűkra és makrőlidőkat tartalmazógyógyszerkészítményekre vőnatkőzik. A szabad vagy védett főrmában, vagy só alakjában létező, találmányszerinti makrőlidőkra az jellemző, hőgy i) a 2-es helyzettől a 6-ős helyzetig piperidazinil-karbőnsav-maradékőt, és/vagy ii) a 7-es helyzettől a 9-es helyzetig arőmás a-aminősav-maradékőt,és/vagy iii) a 10-es helyzettől a 12-es helyzetig alifás a-aminősav-maradékőt főglalnak magűkban. A találmány szerinti makrőlidőkat gőmbatörzsek tenyésztésével állítjákelő. A találmány szerinti hatóanyagőt tartalmazó gyógyszerkészítményektöbbek között az imműnrendszer gátlására, valamint transzplantá-tűmőkkilökődésével járó állapőtők, aűtőimműn betegségek és asztmakezelésére alkalmazhatók. ŕThe invention relates to macrolides, preparations and medicinal preparations containing macrolides. The macrolides according to the invention existing in the free or protected form or in salt form are characterized by i) a piperidazinyl carboxylic acid residue from position 2 to position 6, and/or ii) from position 7 to position 9 an alpha amino acid residue, and/or iii) an aliphatic α-amino acid residue from position 10 to position 12 in the cores. The macarola times according to the invention are produced by breeding gopher strains. Pharmaceutical preparations containing the active ingredient according to the invention can be used, among other things, to inhibit the immune system, as well as to treat conditions associated with rejection of transplanted cells, immune system diseases and asthma. ŕ

HU9802320A 1995-07-04 1996-07-04 Macrolides, procedure of the preparation of macrolides, macrolides containing pharmaceutical products HUP9802320A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9513596.8A GB9513596D0 (en) 1995-07-04 1995-07-04 Organic compounds
GBGB9515495.1A GB9515495D0 (en) 1995-07-28 1995-07-28 Organic compounds

Publications (2)

Publication Number Publication Date
HUP9802320A2 true HUP9802320A2 (en) 1999-02-01
HUP9802320A3 HUP9802320A3 (en) 1999-03-29

Family

ID=26307320

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802320A HUP9802320A3 (en) 1995-07-04 1996-07-04 Macrolides, procedure of the preparation of macrolides, macrolides containing pharmaceutical products

Country Status (17)

Country Link
EP (1) EP0836616A1 (en)
JP (1) JPH11509092A (en)
KR (1) KR19990028724A (en)
CN (1) CN1193979A (en)
AR (1) AR006514A1 (en)
AU (1) AU708004B2 (en)
BR (1) BR9609324A (en)
CA (1) CA2224715A1 (en)
CO (1) CO4750713A1 (en)
CZ (1) CZ424297A3 (en)
HU (1) HUP9802320A3 (en)
IL (1) IL122844A0 (en)
NO (1) NO980016L (en)
PL (1) PL324346A1 (en)
SK (1) SK498A3 (en)
TR (1) TR199800001T1 (en)
WO (1) WO1997002285A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
US7368423B1 (en) * 2001-12-05 2008-05-06 The Scripps Research Institute Composition and method for treating chronic allograft rejection
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
JP2008546708A (en) 2005-06-17 2008-12-25 ノバルティス アクチエンゲゼルシャフト Use of sanglifehrin in HCV
US8067024B2 (en) 2006-02-10 2011-11-29 Medtronic Vascular, Inc. Medical devices to prevent or inhibit restenosis
CN101289440B (en) * 2007-06-29 2010-08-25 中国热带农业科学院热带生物技术研究所 Polyene macrocyclic compounds, preparation thereof and applications
ES2556211T3 (en) 2008-09-24 2016-01-14 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Novel gene pooling
WO2011098808A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
ES2541853T3 (en) 2010-02-09 2015-07-27 Neurovive Pharmaceutical Ab Sangliferin based compounds
WO2011098805A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
GB201008123D0 (en) 2010-05-17 2010-06-30 Biotica Tech Ltd Novel compounds
AR084217A1 (en) 2010-12-10 2013-05-02 Gilead Sciences Inc MACROCICLIC INHIBITORS OF VIRUS FLAVIVIRIDAE
CA2822347C (en) * 2010-12-20 2019-11-05 Neurovive Pharmaceutical Ab Sanglifehrin derivatives and methods for their production
JO3063B1 (en) 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab Novel compound and methods for its production
GB201118334D0 (en) 2011-10-24 2011-12-07 Biotica Tech Ltd Novel dosage form
PL2861604T3 (en) 2012-06-08 2017-08-31 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
AR091279A1 (en) 2012-06-08 2015-01-21 Gilead Sciences Inc MACROCICLIC INHIBITORS OF VIRUS FLAVIVIRIDAE
WO2013185090A1 (en) 2012-06-08 2013-12-12 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
JP2019535726A (en) 2016-11-18 2019-12-12 ネウロビベ プハルマセウトイカル エービー Use of sanglifehrin macrocyclic analogues as anticancer compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9318144D0 (en) * 1993-09-01 1993-10-20 Sandoz Ltd Organic compounds
WO1995015328A1 (en) * 1993-11-30 1995-06-08 Abbott Laboratories Macrocyclic immunomodulators with novel cyclohexyl ring replacements

Also Published As

Publication number Publication date
PL324346A1 (en) 1998-05-25
HUP9802320A3 (en) 1999-03-29
CZ424297A3 (en) 1998-04-15
AR006514A1 (en) 1999-09-08
MX9800217A (en) 1998-07-31
NO980016D0 (en) 1998-01-02
IL122844A0 (en) 1998-08-16
CA2224715A1 (en) 1997-01-23
AU6519396A (en) 1997-02-05
CO4750713A1 (en) 1999-03-31
EP0836616A1 (en) 1998-04-22
KR19990028724A (en) 1999-04-15
BR9609324A (en) 1999-05-25
AU708004B2 (en) 1999-07-29
JPH11509092A (en) 1999-08-17
TR199800001T1 (en) 1998-04-21
WO1997002285A1 (en) 1997-01-23
CN1193979A (en) 1998-09-23
NO980016L (en) 1998-03-02
SK498A3 (en) 1998-07-08

Similar Documents

Publication Publication Date Title
HUP9802320A2 (en) Macrolides, procedure of the preparation of macrolides, macrolides containing pharmaceutical products
FR2442054A1 (en) PURIFIED PROTEINS, IN PARTICULAR INTERFERON, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IE32559B1 (en) Pharmaceutical preparations having an adrenocorticotropic activity
MY121908A (en) 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them.
DE69428040D1 (en) ORAL PHARMACEUTICAL FORM
EP0158277A3 (en) Implantable controlled-release preparations of regulatory peptides, and process for their preparation
EP0221041A3 (en) Benzimidazole derivatives, process for their preparation and their pharmaceutical use
ES541521A0 (en) A PROCEDURE FOR THE PREPARATION OF PIRIDAZINAMINES.
UA29450C2 (en) Derivatives of hydroxamic acid, a PROCESS for PREPARATION thereof, a method for influence on diseases and pharmaceutical composition containing them
HUP0000589A2 (en) Aqueous formulations of peptides
KR960700062A (en) OLIGONUCLEOTIDES MODIFIED TO IMPROVE STABILITY AT ACIC pH Modified to Improve Stability at Acidic pH
RU93004484A (en) DERIVATIVES OF PYRAZOLES, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
FI832355L (en) 9- (2-HYDROXYETOXIMETYL) guanidine derivate
DE3783356T2 (en) BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME.
ES8701228A1 (en) Enkephalinase B inhibitors, their preparation, and pharmaceutical compositions containing the same.
DE68926115D1 (en) METHOD FOR TREATING ACNE
MY129946A (en) Compound with gastric acid inhibitory effect and process for its preparation.
PT81345B (en) METHOD FOR PREPARING NEW ACTIVE PEPTIDEES ON THE CENTRAL NERVOUS SYSTEM WITH ACTION ON THE COLINERGIC SYSTEM, AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
DK149091C (en) METHOD OF ANALOGUE FOR THE PREPARATION OF PEPTIDS CONTAINING 2-7 AMINO ACID RESIDUES, DESAMINODIPEPTIDES OR AMIDES THEREOF WITH UBIQUITIN SIMILAR ACTIVITY OR PHARMACEUTICAL ACCEPTABLE ACID ADDITIONAL SALTS
DE69808938T2 (en) METHOD FOR PRODUCING PHARMACEUTICAL COMPOSITIONS
BR8008818A (en) PHARMACOLOGICALLY ACTIVE PEPTIDES AND MEDICINES CONTAINING THE SAME
DK0413793T3 (en) Concentrated aqueous emulsions, a process for their preparation and their use in the field of pesticides
HUP9901659A2 (en) Use of flupirtin for producing pharmaceutical compositions suitable for the prevention and treatment of diseases which are associated with damage to the haemopoietic cell system
EP0383481A3 (en) Anesthetic oral compositions
CA1307740C (en) Pharmaceutical preparation and method for inhibiting replication of htlv-iii (aids) virus